AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21701060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 9
Study 21701060 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 9
Study 17442602 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine
Number of subjects: 12
Study 17442602 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 12
Study 17442602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (10mg)
Number of subjects: 12
Study 16368074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 87
Study 16368074 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT combined with hypnosis
Number of subjects: 87
Study 16368074 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counselling (SC)
Number of subjects: 87
Study 16368074 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 87
Study 14658582 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical surgery
Number of subjects: 0
Study 14658582 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemo-radiotherapy
Number of subjects: 0
Study 11172237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group therapy
Number of subjects: 0
Study 11172237 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential group therapy
Number of subjects: 0
Study 11172237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9257749 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg intravenously twice a day for 4 days (Group B)
Number of subjects: 16
Study 9257749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg intravenously twice a day for 4 days and Sucralfate 2 g orally three times a day for 7 days (Group A)
Number of subjects: 16
Study 8292694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone Suppression Test (DST) alone
Number of subjects: 166
Study 8292694 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone (TRH) test alone
Number of subjects: 166
Study 8292694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DST and TRH tests
Number of subjects: 166
Study 8292694 — intervention group
Group type: COMPARATOR
Intervention: No neuroendocrine tests administered
Number of subjects: 166
Study 3802690 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release oral morphine sulphate (MS-Contin)
Number of subjects: 0
Study 3802690 — intervention group
Group type: COMPARATOR
Intervention: Solution of oral morphine sulphate
Number of subjects: 0
Study 30595364 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg/d for 6 months
Number of subjects: 36
Study 26498427 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml 0.4% CHO ingested serially via 25 ml boluses
Number of subjects: 10
Study 26498427 — intervention group
Group type: COMPARATOR
Intervention: 375 ml 0% CHO control (CON) ingested followed by one 25 ml 6% CHO mouth rinse
Number of subjects: 10
Study 26498427 — intervention group
Group type: COMPARATOR
Intervention: CON ingest followed by CON rinse
Number of subjects: 10
Study 24784756 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes open alpha power training
Number of subjects: 12
Study 24784756 — intervention group
Group type: COMPARATOR
Intervention: Random beta power training (control)
Number of subjects: 12
Study 22407780 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg)
Number of subjects: 45
Study 22407780 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (50 mg)
Number of subjects: 45
Study 22407780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of curcumin and diclofenac sodium
Number of subjects: 45
Study 20879879 — intervention group
Group type: EXPERIMENTAL
Intervention: R788 100 mg twice daily
Number of subjects: 457
Study 20879879 — intervention group
Group type: EXPERIMENTAL
Intervention: R788 150 mg once daily
Number of subjects: 457
Study 20879879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 19027430 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained coders (EA and AA)
Number of subjects: 8
Study 19027430 — intervention group
Group type: COMPARATOR
Intervention: Untrained coders (EA and AA)
Number of subjects: 8
Study 15992643 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day simvastatin (conventional therapy)
Number of subjects: 51
Study 15992643 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day simvastatin (aggressive therapy)
Number of subjects: 51
Study 15992643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (20 mg and 80 mg simvastatin)
Number of subjects: 51
Study 15992643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reaching mean on-treatment LDL-C < or = 100 mg/dl
Number of subjects: 51
Study 12574182 — intervention group
Group type: EXPERIMENTAL
Intervention: PTHrP (6.56 microg/kg x d, or approximately 400 microg/d)
Number of subjects: 16
Study 12574182 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 16
Study 11360608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 639
Study 11360608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg
Number of subjects: 639
Study 11360608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg
Number of subjects: 639
Study 8722392 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole with successful eradication of H. pylori
Number of subjects: 0
Study 8722392 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole with placebo (failed eradication)
Number of subjects: 0
Study 8722392 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole with amoxycillin (failed eradication)
Number of subjects: 0
Study 1986952 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal support therapy (intramuscular injections of progesterone and/or human chorionic gonadotropin)
Number of subjects: 207
Study 3916369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranicotinate (Perycit) 750 mg daily
Number of subjects: 24
Study 3916369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28084833 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific balance training included in endurance‐resistance training (n=26)
Number of subjects: 49
Study 28084833 — intervention group
Group type: COMPARATOR
Intervention: Resistance‐endurance training only (n=23)
Number of subjects: 49
Study 28084833 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific balance training included in endurance‐resistance training
Number of subjects: 49
Study 27533097 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide impregnated durable wall lining (DWL)
Number of subjects: 1200
Study 27533097 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide treated nets (ITN)
Number of subjects: 1200
Study 27533097 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental management (EM)
Number of subjects: 1200
Study 27533097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1200
Study 24387824 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated volumetric measurements of functional parameters (ADC, AE, VE) before and after intra-arterial therapy (IAT)
Number of subjects: 50
Study 24387824 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated measurements of tumor volume and size in the axial plane before and after IAT
Number of subjects: 50
Study 24387824 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated measurements of change in tumor RECIST size
Number of subjects: 50
Study 24387824 — intervention group
Group type: EXPERIMENTAL
Intervention: EASL measurements of tumor enhancement in the axial plane before and after IAT
Number of subjects: 50
Study 23166343 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-infusion doxorubicin (360 mg/m2 in 30 mg/m2 doses every 3 weeks over 48 hours)
Number of subjects: 102
Study 23166343 — intervention group
Group type: COMPARATOR
Intervention: Bolus-infusion doxorubicin (360 mg/m2 in 30 mg/m2 doses every 3 weeks within 15 minutes)
Number of subjects: 102
Study 20513677 — intervention group
Group type: EXPERIMENTAL
Intervention: Together Facing the Challenge intervention with additional training and consultation to staff and treatment foster parents
Number of subjects: 247
Study 20513677 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual training and treatment
Number of subjects: 247
Study 17989698 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (ALB)
Number of subjects: 101
Study 17989698 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 101
Study 17989698 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (ALB) and Normal saline (NS)
Number of subjects: 101
Study 17588394 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of oral vitamin K
Number of subjects: 40
Study 17588394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17588394 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin cessation 6 days preoperatively
Number of subjects: 40
Study 17588394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg until the evening before surgery
Number of subjects: 40
Study 14996525 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (6-20 mg/d)
Number of subjects: 833
Study 14996525 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC (6/25, 12/25, or 12/50 mg/d)
Number of subjects: 833
Study 14996525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 833
Study 11004094 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical measurement (Orbscan topograph system)
Number of subjects: 18
Study 11004094 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound measurement (standard A-scan)
Number of subjects: 18
Study 9343462 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 361
Study 8450994 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 99
Study 8450994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 8450994 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.3 mg/kg/d
Number of subjects: 99
Study 8450994 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 2 to 2.5 mg/kg/d
Number of subjects: 99
Study 3708119 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 1)
Number of subjects: 14
Study 3708119 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 2)
Number of subjects: 14
Study 3708119 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 3)
Number of subjects: 14
Study 3708119 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 4)
Number of subjects: 14
Study 3708119 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 5)
Number of subjects: 14
Study 3708119 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 6)
Number of subjects: 14
Study 3708119 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 7)
Number of subjects: 14
Study 31536522 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory loading (INSP)
Number of subjects: 10
Study 31536522 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 10
Study 31536522 — intervention group
Group type: EXPERIMENTAL
Intervention: MATCH exercise
Number of subjects: 10
Study 27687681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation, 1500 SW at 18 kV, followed by 1500 SW at 20 kV then 1500 SW at 22 kV
Number of subjects: 150
Study 27687681 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant dose, 4500 SW at 20 kV
Number of subjects: 150
Study 27687681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction, 1500 SW at 22 kV, followed by 1500 SW at 20 kV and then 1500 SW at 18 kV
Number of subjects: 150
Study 26117944 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills (6 g, bid)
Number of subjects: 120
Study 26117944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg, qd)
Number of subjects: 120
Study 26117944 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills plus sertraline
Number of subjects: 120
Study 24620654 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined radiotherapy (34 patients)
Number of subjects: 57
Study 24620654 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (23 patients)
Number of subjects: 57
Study 21455074 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine group (neostigmine 20 μg kg‐1)
Number of subjects: 132
Study 21455074 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (saline)
Number of subjects: 132
Study 19878605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based Green Prescription
Number of subjects: 100
Study 19878605 — intervention group
Group type: COMPARATOR
Intervention: Conventional time-based Green Prescription
Number of subjects: 100
Study 16483622 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (3.6 mg/kg for all i.v. injections, given as three series of three injections separated by 1-week intervals)
Number of subjects: 389
Study 16483622 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (10 consecutive daily i.v. injections of 2.16 mg/kg)
Number of subjects: 389
Study 16483622 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (graded dosing: 1.8, 2.16, 2.52, 2.52, 2.88, 3.24, then 3.6 mg/kg for the last three injections)
Number of subjects: 389
Study 12574768 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Number of subjects: 24
Study 12574768 — intervention group
Group type: COMPARATOR
Intervention: Open tracheostomy
Number of subjects: 24
Study 10839903 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg sufentanil combined with 2.5 mg bupivacaine
Number of subjects: 170
Study 10839903 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 microg sufentanil combined with 2.5 mg bupivacaine
Number of subjects: 170
Study 10839903 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg sufentanil combined with 2.5 mg bupivacaine
Number of subjects: 170
Study 10839903 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 microg sufentanil combined with 2.5 mg bupivacaine
Number of subjects: 170
Study 10839903 — intervention group
Group type: COMPARATOR
Intervention: Control (0 microg sufentanil combined with 2.5 mg bupivacaine)
Number of subjects: 170
Study 10839903 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 microg sufentanil
Number of subjects: 170
Study 10839903 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 and 10.0 microg sufentanil
Number of subjects: 170
Study 10839903 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (2.5, 5.0, 7.5, 10.0 microg sufentanil)
Number of subjects: 170
Study 9352866 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg three times daily)
Number of subjects: 118
Study 9352866 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 118
Study 8222480 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg extended‐release felodipine once daily for 2 weeks
Number of subjects: 12
Study 8222480 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 2 weeks
Number of subjects: 12
Study 3811793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogan (ketobemidone 5 mg + A-29 25 mg)
Number of subjects: 227
Study 3811793 — intervention group
Group type: COMPARATOR
Intervention: Morphine + scopolamine (10 mg + 0.4 mg)
Number of subjects: 227
Study 31002403 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver assessment documentation
Number of subjects: 211
Study 31002403 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver support provision
Number of subjects: 211
Study 31002403 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported relationship problems
Number of subjects: 211
Study 29716449 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Skills for Work program (enhanced supported employment plus cognitive remediation)
Number of subjects: 107
Study 29716449 — intervention group
Group type: COMPARATOR
Intervention: Enhanced supported employment only
Number of subjects: 107
Study 27107287 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (AS-MQ)
Number of subjects: 103
Study 27107287 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 103
Study 25273932 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme (low-to-moderate intensity, 3 times a week for 12 weeks)
Number of subjects: 55
Study 25273932 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained current lifestyle)
Number of subjects: 55
Study 22192641 — intervention group
Group type: EXPERIMENTAL
Intervention: LC15-0444 200 mg
Number of subjects: 0
Study 22192641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Number of subjects: 0
Study 22192641 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of LC15-0444 and pioglitazone
Number of subjects: 0
Study 20014133 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol supplementation
Number of subjects: 10
Study 20014133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17921364 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight velocity from 1 y and 9 mo to 5 y of age
Number of subjects: 679
Study 17921364 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant weight gain from 5 mo to 1 y and 9 mo
Number of subjects: 679
Study 15812582 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (screening visit with lifestyle questionnaire and quantitative ultrasound heel scan)
Number of subjects: 5306
Study 15812582 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 5306
Study 15812582 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5306
Study 11570381 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze procedure with SICTRA (20 to 32 W; 200 to 320 mL/h saline)
Number of subjects: 30
Study 11570381 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze procedure with SICTRA
Number of subjects: 30
Study 11570381 — intervention group
Group type: COMPARATOR
Intervention: Control group (without Maze procedure)
Number of subjects: 30
Study 9551875 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg once daily
Number of subjects: 231
Study 9551875 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 231
Study 7941939 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.5% 2.5 mg kg‐1
Number of subjects: 30
Study 7941939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural bupivacaine)
Number of subjects: 30
Study 7941939 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 30
Study 2896555 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551 10 mg
Number of subjects: 5
Study 2896555 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551 20 mg
Number of subjects: 5
Study 2896555 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551 50 mg
Number of subjects: 5
Study 2896555 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551 100 mg
Number of subjects: 5
Study 2896555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29569254 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC (bone marrow-derived mononuclear cells)
Number of subjects: 121
Study 29569254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 29569254 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC
Number of subjects: 121
Study 29569254 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC and Placebo
Number of subjects: 121
Study 27382814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine with rectal diclofenac (100mg diclofenac suppository and 30mg intramuscular pentazocine)
Number of subjects: 130
Study 27382814 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine alone (30mg intramuscular pentazocine)
Number of subjects: 130
Study 24831517 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective antiretroviral therapy (ART)
Number of subjects: 0
Study 24831517 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of ART within six months of infection
Number of subjects: 0
Study 24831517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD4/CD8 ratio during effective ART
Number of subjects: 0
Study 21797916 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal gel and placebo pills
Number of subjects: 22
Study 21797916 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 10 g/day plus placebo pills
Number of subjects: 22
Study 21797916 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 10 g/day plus the aromatase inhibitor anastrozole 1 mg/day
Number of subjects: 22
Study 20433732 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS version of the WOMAC scale
Number of subjects: 221
Study 18054753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of 32-week peginterferon alfa-2b and 2-year lamivudine
Number of subjects: 26
Study 15607598 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate systemic hypothermia (33 degrees C) for 48 hours
Number of subjects: 65
Study 15607598 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37 degrees C) for 48 hours
Number of subjects: 65
Study 15607598 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcome of death or severe motor scores
Number of subjects: 65
Study 12169076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-rubbing protocol with 75% aqueous alcoholic solution containing propanol‐1, propanol‐2, and mecetronium etilsulfate
Number of subjects: 4387
Study 12169076 — intervention group
Group type: COMPARATOR
Intervention: Hand-scrubbing protocol with antiseptic preparation containing 4% povidone iodine or 4% chlorhexidine gluconate
Number of subjects: 4387
Study 12169076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-rubbing protocol
Number of subjects: 4387